Table 2 Designs of the identified studies evaluating restriction policies for pregabalin
From: A systematic review of the effectiveness of policies restricting access to pregabalin
| Â | Margolis et al., 2009 [27] | Margolis, et al., 2010 [28] | Bazalo et al., 2010 [26] | Udall et al., 2014 [30] | Suehs et al., 2014 [31] | Placzek et al., 2014 [29] | Null et al., 2016 [32] | Martin et al., 2016 [33] |
|---|---|---|---|---|---|---|---|---|
Study design (population) | Retrospective database (Medicaid) | Retrospective database (commercial) | Modeling (IMS prescription data) | Retrospective database (commercial) | Retrospective database (Medicare) | Retrospective database (commercial) | Retrospective database (Medicare & commercial) | Retrospective database (commercial) |
Number of patients | Restricted, n = 424; unrestricted, n = 5153 | Restricted, n = 2084; unrestricted, n = 1320 | Not applicable | Restricted, n = 3876; unrestricted, n = 3876 | Restricted, n = 13,911; unrestricted, n = 13,911 | Restricted, n = 29,283; unrestricted, n = 463 | Not applicable | Restricted, n = 1218; unrestricted, n = 1218 |
Restriction type | PA | PA | PA | ST | ST | PA | ST | Mail order requirement |
Conditions evaluated | PHN; pDPN | PHN; pDPN | PHN; pDPN; FM; partial-onset seizures | PHN; pDPN; FM | PHN; pDPN | pDPN; FM | pDPN; FM; PHN | PHN; pDPN; FM; partial-onset seizures |